The GLP-1 Gold Rush: Who Should Really Be Taking Ozempic?

A shocking investigation reveals the massive gap between Ozempic and Wegovy's marketing claims and the actual scientific evidence. Pharmaceutical companies are touting these GLP-1 drugs as a universal weight loss solution, but the data tells a dramatically different story. Discover how a seemingly impressive '20% reduction' in cardiovascular events shrinks to a mere 1.5% absolute risk reduction when you examine the fine print. We'll break down the real-world prescription trends, showing that 73.8% of users are taking these drugs off-label, with most having underlying health conditions. Learn why these medications aren't the miracle cure they're marketed as—with most users stopping treatment within a year and regaining two-thirds of their lost weight. A quick note—the opinions and analysis shared on Truth Seekers are our own interpretations of published research and should not be used as medical, financial, or professional advice. Always consult qualified professionals for decisions affecting your health or wellbeing.